Zandelisib

DB18245InvestigationalSmall molecule

Zandelisib: Overview.

Mechanism: Pharmacologically active on Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform
Curator reviewed
Formula / weight: C₃₁H₃₈F₂N₈O · 576.697 g/mol (avg)
Also known as: 1,3,5-triazin-2-amine, 4-(2-(difluoromethyl)-1h-benzimidazol-1-yl)-n-(1,1-dimethyl-2-(2-(1-methyl-4-piperidinyl)phenyl)ethyl)-6-(4-morpholinyl)- · 4-(2-(difluoromethyl)benzimidazol-1-yl)-n-(1,1-dimethyl-2-(2-(1-methyl-4-piperidyl)phenyl)ethyl)-6-morpholino-1,3,5-triazin-2-amine
Code names: ACC-524 · ME-401 · PW-143 · PWT-143

Resolves to

Compound

Structure

InChIKeyWPFUFWIHMYZXSF-UHFFFAOYSA-NSMILESCN1CCC(CC1)C1=CC=CC=C1CC(C)(C)NC1=NC(=NC(=N1)N1C(=NC2=CC=CC=C12)C(F)F)N1CCOCC1

Targets

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

9Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Zandelisib, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.